***

Prime editing is a gene-editing technology that corrects faulty parts of genes with greater precision. While conventional CRISPR is closer to a method of cutting DNA and then repairing it, prime editing is closer to selecting only the desired part and changing it as if revising a sentence. In other words, rather than being like scissors that cut through a gene all at once, it is more like a pen that carefully finds and corrects a typo, which is why researchers believe this technology may be able to fix a wider range of genetic errors while reducing unwanted damage. In one line, prime editing is a next-generation gene-editing technology that aims to correct typos in genes more accurately and safely.

Gene editing is no longer just a laboratory technology; it is entering clinical medicine as an option for treating actual patients. The next step is not about cutting more aggressively, but about correcting more precisely and more safely. The first human application of prime editing is a symbolic scene showing that this transition has begun.

In May 2025, Nature introduced the first case in which prime editing was used in an actual person. The patient was someone with a rare disease in which an inherited genetic abnormality causes problems with immune function from birth. The researchers carried out the treatment by taking stem cells out of the patient’s body, correcting the faulty part of the gene, and then putting those cells back into the body. The purpose of this trial was to examine both how safe this treatment is in humans and whether it can actually help restore immune function. Later, initial results from its use in two patients were published in a medical journal, making it clear that prime editing is no longer just a laboratory story.

What makes this moment special is not simply its symbolism as a “first.” The moment any technology is actually applied to a person, the questions surrounding it change completely. In the laboratory, the focus is on editing efficiency, accuracy, and theoretical superiority. In the clinic, however, a very different language appears. How safe is it? Will problems remain over time? Can it be reproduced at the same level in different patients? Are manufacturing and quality control stable? Is the cost manageable? Who gets access first? The moment a scientific idea becomes a medical reality, the technology no longer belongs only to researchers. It becomes a social object borne collectively by hospitals, regulators, manufacturing facilities, insurance systems, and patient communities.

That is why the first human application always has two faces. One side exaggerates it as though the future has already arrived, while the other dismisses it as merely a single case. But from the perspective of the history of technology, what matters lies somewhere in between. One case cannot establish generalizability, but because that one case exists, it becomes possible to ask far more realistic questions. What worked well, what remains uncertain, which patients can be treated first, and how much safety data must accumulate before moving to the next stage can finally begin to be examined in the language of clinical medicine. The first human application of prime editing is significant precisely because it crossed that threshold.

Medical innovation tends to grow first in the places of greatest urgency. Even when patient numbers are small, fields in which the cause of disease is relatively clear, the limits of existing treatment are obvious, and there is sufficient reason to take the risk of trying something new are the ones that first adopt a technology. That is why gene therapy and gene editing first cross the clinical threshold in rare genetic diseases. The clearer it is where the problem lies, the more meaningful it becomes to try to correct the defect itself rather than simply slow or ease the symptoms. Chronic granulomatous disease shows these conditions well. Because of a specific genetic abnormality, immune cells fail to function properly, and patients suffer repeated infections and inflammation. In such a case, the idea of correcting the defect at the genetic level does not feel like some vague future technology; it becomes a very realistic therapeutic strategy.

But rare disease is a starting point, not necessarily the destination. Gene editing technologies generally aim to prove safety and functional feasibility in rare diseases first, then gradually expand into more common conditions. In fact, the gene editing industry has recently begun looking not only at immune and blood disorders but also at much larger fields such as cardiovascular disease. The meaning of this trend is simple: gene editing no longer intends to remain only an exceptional treatment for a very small number of patients. As safety, delivery technology, and manufacturing experience accumulate, it seeks in the long term to become part of a much broader healthcare system. The first human application of prime editing can be read as the opening scene of that potential expansion.

What matters here is abandoning the view of rare disease as merely a “small market.” In the history of medicine, rare diseases have often been the place where the most advanced technologies first became real. The number of patients may be small, but the essence of the disease is clear and the gaps in existing treatment are large, making it an ideal setting for a technology to demonstrate real value. And the manufacturing, safety, and regulatory experience built in that process ultimately carries over into wider fields. In other words, rare disease is not the periphery; it is often the front-line testing ground of medical innovation. Prime editing is now walking that very path.

The easiest way to understand prime editing is not to think of it simply as “an upgraded pair of gene scissors.” If conventional gene editing became widely known as a method that cuts DNA and then relies on the cell’s repair process, prime editing is an approach that seeks to make the desired sequence changes more precisely while minimizing unnecessary damage. To use an analogy, it is closer to carefully correcting a misspelled word than to cutting up and pasting back an entire sentence. This analogy does not capture every technical detail, but it does show intuitively why prime editing is called a next-generation editing tool. The essence lies not in “cutting more,” but in “changing more accurately while causing less harm.”

This difference is not just a matter of technological boasting. The greatest anxiety that gene editing has generated both among the public and in clinical settings has always been unpredictability. Will something other than the intended target also be changed? Does the editing process place excessive stress on cells? Even if everything looks fine now, could an unexpected problem emerge years later? Because gene editing, once introduced into the body, is not as easily stopped or reversed as a drug, people ask about trust before they ask about efficiency. Prime editing draws attention for this reason. It is not because it is a more dazzling technology, but because it inspires hope that it may reduce “unwanted changes,” the oldest fear surrounding gene editing.

From the perspective of doctors and patients, this distinction becomes even more important. A doctor needs a much higher level of confidence before recommending an intervention that is difficult to reverse. Patients and families also do not look only at the possibility of improvement. They think at the same time about whether something irreversible might happen, whether things could become worse than they are now. That is why what will determine the future of gene editing is not technological flashiness, but whether safety can be convincingly established through accumulated data. The fact that prime editing has entered the stage of human application does not mean the era of technological self-congratulation has begun; it means a far stricter test centered on trust has begun.

Saying that the first human application is important does not merely refer to its historical symbolism. The moment a technology enters an actual patient, it becomes a systems problem. Regulators must decide what data standards to use in evaluating approval. Hospitals must design actual procedures for cell collection, editing, reinfusion, and follow-up management. Manufacturing facilities must maintain consistent quality from patient to patient. In addition, questions of cost and insurance, long-term adverse-event monitoring, patient selection criteria, and informed consent all come attached. A single patient’s treatment therefore becomes more than an individual event; it becomes a trigger that moves the entire medical system.

This is also why the follow-up clinical results are drawing attention. According to what was published in a medical journal, after this treatment was given to two patients, their immune cells and blood cells were seen to settle into the body relatively quickly. It also appeared that the immune function needed to fight infections was maintained for several months. This suggests that the gene-corrected stem cells had begun to do their job to some extent inside the body. However, there were side effects related to a drug that was used before the treatment, and because the number of patients treated so far is still very small, it remains necessary to watch more closely whether the treatment is still safe after a long period of time and whether similar results will appear in other patients. In other words, the first step was taken successfully, but how long and how safe this path will be still has to be confirmed from this point on.

At this point, what matters is not simply saying “it succeeded,” but also seeing clearly “what still remains unresolved.” Can the edited cells continue to function stably after one year, three years, five years? Will similar results be reproduced in patients with different genetic backgrounds? Could immunologic or hematologic abnormalities appear later? Can the manufacturing process maintain the same quality across multiple medical centers and patient groups? The first case opens the door, but widening that door and turning the approach into an actual standard of care will ultimately depend on repeated data and time. Prime editing has only just entered the starting line of that long process.

When people think of gene therapy, they often picture gene sequences and the precision of molecular biology first. Of course, that is central. But in the real world of treatment, process matters just as much. The entire chain of removing cells, editing them, reinfusing them into the patient, and continuing long-term follow-up does not run on laboratory ideas alone. It is also a production system, a logistics system, and a quality-control system. Especially in personalized cell therapy, even a small deviation can shake the entire outcome, so the distance between “it worked once” and “it can be done repeatedly and stably” is great.

The public usually asks first, “How accurately was it corrected?” But in clinical settings, the more urgent questions often lie elsewhere. Can this treatment be implemented at a similar level in other hospitals? How much can the failure rate in the manufacturing process be reduced? How will variation among patients be managed? Who will bear the cost of long-term follow-up and adverse-event monitoring? In the end, the price of treatment is often determined less by the gene itself than by the production line and operational system. No matter how precise gene editing becomes, if the process is unstable it cannot be widely used, and if the cost is too high it may remain a technology accessible only to a tiny few.

In the history of medicine, the technologies that changed the world were not always the most astonishing ones. Often, the winners were the technologies that operated most reliably. Technologies that could be produced more easily, delivered more consistently, and reached more patients ultimately became the standard. Prime editing is likely to face the same test. No matter how precise the editing may be, if the treatment process remains too complex and the cost too high, it will be difficult for it to grow into a technology that changes the healthcare system as a whole. Conversely, if manufacturing, delivery, and follow-up systems mature, this technology may expand beyond rare diseases into much broader areas of medicine. The real contest will not end at molecular precision; it will likely be decided by the maturity of the process.

The stronger a technology becomes, the more the final question always comes down to human choice. In what cases, for whom, and how far should it be applied? Using the same gene editing technology to treat life-threatening rare disease and to lower disease risk in advance or enhance physical function places that technology in entirely different ethical landscapes. So far, social consensus has been relatively easy because the focus has been on rare-disease treatment. Existing therapies are insufficient, patient suffering is great, and alternatives are few. But if the technology moves into broader disorders, and beyond that into the realms of prevention or enhancement, the story becomes far more complex.

At that point, a simple pro-versus-con debate is no longer enough. Questions come all at once: what should count as treatment, where enhancement begins, how society should respond if expensive gene editing therapies become concentrated in certain classes, and how far public insurance should go in covering them. Medicine begins with technology, but in the end it is completed on top of rules, institutions, and systems of priority. The first human application of prime editing is therefore less a declaration that “gene editing has become more powerful” than a signal that society must now deal with this technology as a real option. Once a technology has entered a person, it no longer remains only a debate about the future.

In the end, the true testing ground for prime editing is not the laboratory alone. Hospitals, regulators, insurance systems, patient communities, and the public’s perception of the technology will all shape its future. That is why the first human application is not the end, but the beginning. Gene editing is now moving beyond the realm of science into the realms of medicine and industry, institutions and ethics. And for precisely that reason, the first step of prime editing should be read not simply as the story of one patient, but as the first sentence in a long narrative about how far medicine itself may change.

Nature, 2025-05-19, “World first: ultra-powerful CRISPR treatment trialled in a person”